Trial Profile
Randomized, Placebo Controlled, Double Blind Phase 1b/2 Study of U3-1287 (AMG 888) in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed HER2 Positive Metastatic Breast Cancer (MBC)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Patritumab (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 13 Oct 2017 Status changed from active, no longer recruiting to discontinued.
- 25 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrial.gov record.
- 23 May 2015 Planned number of patients changed from 86 to 29 as reported by ClinicalTrial.gov record.